A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the novel oral agent VT-1161 is safe and
effective in treating patients with moderate - severe tinea pedis (also referred to as
athletes foot). VT-1161 has been designed to inhibit CYP51, an enzyme essential for fungal
growth. Inhibition of CYP51 results in the accumulation of chemicals know to be toxic to the
fungus. CYP51 is the molecular target of the class of drugs referred to as 'azole
antifungals'. All currently approved azole drugs have poor selectivity for CYP51 and this
results in many of the side effects associated with the azole antifungals. The safety profile
of the class similarly limits use in chronic treatment of non-life-threatening fungal
infections. A safer antifungal drug would improve treatment options for infections seen in
otherwise healthy individuals where significant side-effect risks are unacceptable.